‘Looksmaxxing’ Trend Spawns $100M Gray Market Fueled By Bitcoin, Stablecoins: Chainalysis

A fast-growing gray market for peptides has become one of cryptocurrency’s newest high-volume markets, according to a report released Thursday by Chainalysis, processing more than $100 million annually primarily through Bitcoin and stablecoin payments.

The blockchain data firm found that crypto flows to peptide vendors jumped from roughly $12 million in the fourth quarter of 2025 to $32 million in the first quarter of 2026, a 159% increase. The market is on pace to process about $39 million in the second quarter, the firm said.

“What began as a quiet, underground community of biohackers using crypto to bypass traditional gatekeepers has since mutated into a financial juggernaut,” Chainalysis wrote. “Fueled first by sudden political legitimacy and later by a viral internet subculture known as ‘looksmaxxing,’ the on-chain peptide ecosystem is experiencing a breakout.”

Looksmaxxing is a social media-driven trend focused on maximizing physical attractiveness through fitness, grooming, diet, supplements, cosmetic procedures, and other appearance-enhancing interventions. Unlike biohacking, which generally aims to improve health, performance, or longevity, looksmaxxing is primarily focused on appearance.

Peptides are short chains of amino acids used in medical and cosmetic treatments, including the active ingredients behind popular weight-loss drugs such as Ozempic and Wegovy. While the availability and cost of these drugs have decreased under President Donald Trump’s administration, demand for cheaper alternatives has fueled a growing network of overseas suppliers selling unbranded peptide products directly to consumers.

Unlike earlier online black markets like the Silk Road, Chainalysis said gray markets gained popularity during the rise of the Make America Healthy Again movement and growing interest in alternative health approaches, but have accelerated sharply in early 2026. The firm estimates the sector is now processing tens of millions of dollars in cryptocurrency each quarter, putting it on pace to exceed a $100 million annual run rate.

Many vendors, the report said, rely on Bitcoin and stablecoins due to banks and payment processors restricting payments related to unapproved pharmaceutical compounds, with many of the larger operators increasingly favoring stablecoins—which are typically pegged to the dollar and reduce exposure to crypto market price swings.

“This preference for stability becomes especially pronounced at the wholesale level,” Chainalysis wrote. “When isolating vendors that average $1,000 or more per deposit, the asset mix shifts heavily toward majority stablecoins—a potentially calculated move to insulate massive supply chain orders from the unpredictable price fluctuations of the broader crypto market.”

Separately, the firm identified several Chinese chemical manufacturers that it says moved into peptide sales after previously supplying fentanyl and amphetamine precursors, including Shanghai Sigma Audley and Bigreat Technology.

“By transitioning to gray-market peptides, these China-based suppliers are now selling highly coveted, finished products directly to the end consumer,” the report said. “This direct-to-consumer model allows them to cut out the cartel middlemen, capture the full retail profit margin, and vastly increase their revenue while simultaneously lowering their legal risk.”

Chainalysis did not immediately respond to a request for comment by Decrypt.